531040-3 ; 933210
Lehr- und Forschungsgebiet Translationale Hämatologie und Onkologie Also known as:933220| ID | I:(DE-82)531040-3_20140620 |
All known publications ...
Download: BibTeX | EndNote XML, Text | RIS |
Abstract/Journal Article
Bomedemstat Versus Hydroxyurea in Essential Thrombocythemia Naive to Cytoreductive Therapy: Phase 3 Shorespan-007 Study
65. Annual Scientific Meeting of the British Society for Haematology, BSH 2025, GlasgowGlasgow, UK, 27 Apr 2025 - 29 Apr 2025
British journal of haematology : BJHaem 206(S1), BSH25-EP30 (2025)
Homepage of journal
BibTeX |
EndNote:
XML,
Text |
RIS
Journal Article
Final Results From a Large, Non-Interventional, Phase 4 Study of Ruxolitinib for the Treatment of Myelofibrosis in Clinical Routine
European journal of haematology 115(4), 380-390 (2025) [10.1111/ejh.70005]
Files
BibTeX |
EndNote:
XML,
Text |
RIS
Journal Article
Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor–Naive or –Experienced Myelofibrosis Treated With Momelotinib
Clinical lymphoma, myeloma & leukemia 25(3), 199-211 (2025) [10.1016/j.clml.2024.10.001]
Files
BibTeX |
EndNote:
XML,
Text |
RIS
Journal Article
A hepatocellular carcinoma model with and without parenchymal liver damage that integrates technical and pathophysiological advantages for therapy testing
Pharmacological research 211, 107560 (2025) [10.1016/j.phrs.2024.107560]
Files
BibTeX |
EndNote:
XML,
Text |
RIS
Journal Article
Cell Adhesion and Local Cytokine Control on Protein‐Functionalized PNIPAM‐co‐AAc Hydrogel Microcarriers
Small : nano micro 21(2), 2404183 (2024) [10.1002/smll.202404183]
Files
BibTeX |
EndNote:
XML,
Text |
RIS
Abstract/Journal Article/Contribution to a conference proceedings
Transfusion Intensity Over Time in Patients From the Phase 3 SIMPLIFY-1 and MOMENTUM Trials of Momelotinib
12. Annual Meeting of the Society of Hematologic Oncology, SOHO 2024, Houston, TXHouston, TX, USA, 4 Sep 2024 - 7 Sep 2024
Clinical lymphoma, myeloma & leukemia$a 10.1016/S2152-2650(24)01392-2 24(Supplement 1), MPN-088 (2024) [10.1016/S2152-2650(24)01392-2] special issue: "Proceedings of the Society of Hematologic Oncology 2024 Annual Meeting : 4-7 September 2024, Houston, Texas, USA & Virtual Venue (Hybrid Event)"
BibTeX |
EndNote:
XML,
Text |
RIS
Journal Article
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options
Ann Hematol 103(7), 2299-2310 (2024) [10.1007/s00277-024-05665-4]
Files
BibTeX |
EndNote:
XML,
Text |
RIS
Journal Article
Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis
Blood : journal of the American Society of Hematology 144(17), 1813-1820 (2024) [10.1182/blood.2024025802]
BibTeX |
EndNote:
XML,
Text |
RIS
Journal Article
Oncogenic Calreticulin Induces Immune Escape by Stimulating TGFβ Expression and Regulatory T-cell Expansion in the Bone Marrow Microenvironment
Cancer research 84(18), 2985-3003 (2024) [10.1158/0008-5472.CAN-23-3553]
BibTeX |
EndNote:
XML,
Text |
RIS
Contribution to a book
Ph-negative myeloproliferative Neoplasien
Therapie-Handbuch Onkologie und Hämatologie / Hubert Serve und David Zurmeyer (Hrsg.) ; mit Beiträgen von: Lukas Aguinarte, Frankfurt a.M. [und vielen weiteren]
München : Elsevier, Therapie-Handbuch : 2. Auflage, 219-227 (2024) [10.1016/B978-3-437-21011-2.00031-4]
BibTeX |
EndNote:
XML,
Text |
RIS
All known publications ...
Download: BibTeX | EndNote XML, Text | RIS |